Eva Poveda

Learn More
Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection. It specifically inhibits the replication of R5 viruses by blocking viral entry. HIV-1 tropism can be estimated accurately and predict viral response to maraviroc. Genotypic tools are increasingly replacing phenotypic assays in most places. The favorable pharmacokinetic(More)
INTRODUCTION In a previous interim 24-week virological safety analysis of the PROTEST study (1), initiation of Maraviroc (MVC) plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs) in aviremic subjects based on genotypic tropism testing of proviral HIV-1 DNA was associated with low rates of virological failure. Here we present the final 48-week(More)
BACKGROUND The US Centers for Disease Control and Prevention (CDC) recently add the advice of one-time testing of HCV infection in persons born during 1945-1965. Moreover, the US Preventive Services Task Force (USPSTF) newly recommended one-time HIV testing for persons aged 15-65. Herein, we evaluate the potential impact of these recommendations in a(More)
Purpose To evaluate the influence of HIV-1 tropism on virologic and immunologic responses in antiretroviral-naïve HIV-1-infected patients enrolled in the ArTEN trial (atazana-vir/r vs. nevirapine along with tenofovir/emtricitabine). Methods Baseline plasma samples from patients enrolled in the ArTEN trial were tested genotypically for HIV tropism using(More)
  • 1